Can chicken cause gynaecomastia? It is a question that has gained traction online, fuelled by concerns about hormones in poultry farming. Gynaecomastia — the benign enlargement of glandular breast tissue in males — affects an estimated 30–60% of men at some point in their lives and is driven by an imbalance between oestrogen and testosterone. While dietary factors are frequently blamed, the reality is more nuanced. This article examines the science behind chicken consumption and hormone levels, reviews the genuine causes of gynaecomastia, and outlines when to seek medical advice under current NHS and NICE guidance.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by an elevated oestrogen-to-androgen ratio. Established causes include medications, hypogonadism, obesity, alcohol, and rarely hormone-secreting tumours.

Have any more questions about this? Message our pharmaceutical team to get more info →

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males. It is a relatively common condition, affecting an estimated 30–60% of men at some point during their lifetime, with peaks occurring during puberty, middle age, and older adulthood. It is important to distinguish true gynaecomastia — which involves actual glandular tissue proliferation — from pseudogynaecomastia, which is caused by excess fatty tissue in the chest area without glandular involvement.

The underlying mechanism of gynaecomastia centres on a hormonal imbalance, specifically an elevated ratio of oestrogen to androgen (testosterone) activity within breast tissue. Oestrogens stimulate ductal and stromal growth in the breast, while androgens counteract this effect. When this balance is disrupted — whether through increased oestrogen production, reduced testosterone levels, or heightened sensitivity of breast tissue to oestrogen — glandular enlargement can occur.

Established causes include:

• Physiological changes during puberty or ageing

• Medications — several medicines have a well-established association, including spironolactone, bicalutamide and other anti-androgens, finasteride and dutasteride (5-alpha-reductase inhibitors), cimetidine, digoxin, efavirenz, ketoconazole, anabolic steroids, and some antipsychotics. Proton pump inhibitors and certain antidepressants have been reported in case reports but represent weaker, less certain associations

• Medical conditions such as hypogonadism, hyperthyroidism, liver cirrhosis, and chronic kidney disease

• Recreational drug and alcohol use — alcohol and anabolic steroids have the strongest evidence; cannabis has been reported in association but the evidence is mixed and uncertain

• Tumours of the testes, adrenal glands, or pituitary gland (rare but important to exclude)

In many cases, no clear cause is identified, and the condition is labelled idiopathic. Understanding the hormonal basis of gynaecomastia is essential when evaluating whether dietary factors — such as chicken consumption — could plausibly contribute to its development.

Important: if you are taking a prescribed medicine that you think may be contributing to gynaecomastia, do not stop taking it without first discussing this with your GP or prescriber.

Does Eating Chicken Affect Hormone Levels in Men?

Eating chicken within a normal balanced diet does not meaningfully raise circulating oestrogen levels in men. Hormonal growth promoters in poultry are illegal in the UK, and endogenous oestrogens in chicken are present only in negligible quantities.

A widely circulated concern is that eating chicken — particularly commercially farmed chicken — may raise oestrogen levels in men and thereby contribute to gynaecomastia. This concern largely stems from historical practices in some countries where hormonal growth promoters were used in poultry farming to accelerate weight gain. However, it is important to contextualise this within current UK regulatory standards.

In the United Kingdom, the use of hormonal growth promoters in food-producing animals — including poultry — is illegal under retained EU law, including the provisions of Directive 96/22/EC. Compliance is enforced by the Veterinary Medicines Directorate (VMD) and the Food Standards Agency (FSA), which also oversee controls on residues in food and on imports from countries where such practices may differ. Chicken sold through UK retailers and food service outlets must meet these standards.

Chicken does naturally contain trace amounts of endogenous animal oestrogens, as all animal-derived foods do. It is important to note that these are not the same as plant phytoestrogens (such as isoflavones and lignans found in soya, flaxseed, and legumes), which interact with oestrogen receptors differently and with generally lower potency. The quantities of endogenous oestrogens present in a typical serving of chicken are extremely small, and the human body produces oestrogen endogenously in quantities that vastly exceed dietary intake from meat sources.

At present, there is no robust scientific evidence to suggest that eating chicken within a normal, balanced diet meaningfully raises circulating oestrogen levels in men or directly causes gynaecomastia. While it is reasonable to be mindful of food quality and sourcing, attributing gynaecomastia to chicken consumption alone is not supported by current clinical or nutritional evidence.

The Evidence on Dietary Oestrogens and Breast Tissue Growth

No high-quality evidence links chicken consumption to gynaecomastia. Diet-related cases typically involve extreme intake of phytoestrogen-rich foods, not standard poultry consumption.

The broader question of whether dietary compounds that interact with oestrogen receptors can influence breast tissue in men is a legitimate area of scientific enquiry, though the evidence remains nuanced and, in many cases, inconclusive.

Phytoestrogens are plant-derived compounds (including isoflavones and lignans) that weakly interact with oestrogen receptors in the body. They are found in foods such as soya products, chickpeas, lentils, and flaxseeds. Some case reports have described gynaecomastia in men consuming very large quantities of soya-based products, though these cases involved unusually high intake levels far beyond typical dietary consumption. Mainstream dietary exposure to phytoestrogens is not considered a clinically significant cause of gynaecomastia in the general male population, a position consistent with assessments by the European Food Safety Authority (EFSA) and NHS guidance.

Xenoestrogens are synthetic or environmental oestrogen-like compounds found in certain plastics, pesticides, and industrial chemicals. There is ongoing research into their potential endocrine-disrupting effects, but evidence directly linking normal dietary exposure to gynaecomastia in humans remains limited and largely preclinical.

Key points from the available evidence:

• No high-quality randomised controlled trials have demonstrated that chicken consumption causes gynaecomastia

• Isolated case reports of diet-related gynaecomastia typically involve extreme or unusual dietary patterns

• The EFSA and the NHS do not list chicken consumption as a risk factor for gynaecomastia

• Hormonal disruption is far more likely to arise from alcohol, exogenous anabolic steroids, or obesity (which increases peripheral conversion of androgens to oestrogens via aromatase activity in adipose tissue) than from typical dietary intake

In summary, while dietary factors can theoretically influence hormone balance, the evidence does not support chicken as a meaningful contributor to gynaecomastia under normal dietary conditions.

Other Common Causes of Gynaecomastia to Be Aware Of

Medications such as spironolactone, finasteride, and anabolic steroids are among the most common causes of gynaecomastia. Obesity, alcohol, and hypogonadism are also well-established contributors.

Given that chicken consumption is unlikely to be a significant cause of gynaecomastia, it is clinically important to consider the well-established and more probable causes of the condition. Identifying the underlying aetiology is essential for appropriate management.

Medications are among the most common causes of drug-induced gynaecomastia. Medicines with a well-established association include:

• Spironolactone and other anti-androgens (e.g., bicalutamide, cyproterone acetate)

• Finasteride and dutasteride (5-alpha-reductase inhibitors used for benign prostatic hyperplasia and hair loss)

• Cimetidine (an H2-receptor antagonist)

• Digoxin

• Efavirenz (an antiretroviral)

• Ketoconazole (systemic antifungal)

• Anabolic steroids and testosterone replacement therapy (paradoxically, through aromatisation to oestradiol)

• Some antipsychotics (via hyperprolactinaemia)

• Chemotherapy agents such as alkylating agents

Proton pump inhibitors and certain antidepressants have been reported in association with gynaecomastia, but these represent weaker, less certain associations based largely on case reports.

Important: do not stop any prescribed medicine without first discussing this with your GP or specialist. If you suspect a medicine is causing gynaecomastia, your clinician can advise on whether an alternative agent is appropriate. Suspected adverse drug reactions can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Obesity is a particularly important and underrecognised cause. Excess adipose tissue increases the activity of the enzyme aromatase, which converts androgens into oestrogens. This peripheral conversion can significantly elevate oestrogen levels relative to testosterone, promoting breast tissue growth.

Alcohol consumption, particularly heavy or chronic use, can impair hepatic metabolism of oestrogens and suppress testosterone production, creating a hormonal environment conducive to gynaecomastia.

Hypogonadism — whether primary (testicular failure) or secondary (pituitary or hypothalamic dysfunction) — reduces testosterone production and shifts the androgen-to-oestrogen ratio unfavourably.

Less commonly, oestrogen-secreting tumours of the adrenal glands or testes, as well as hyperthyroidism and chronic liver disease, may be responsible. These causes, though rare, must be excluded through appropriate investigation, particularly when gynaecomastia is unilateral, rapidly progressive, or associated with other symptoms such as testicular masses or systemic illness.

When to See a GP About Gynaecomastia

See your GP if you notice a firm or tender breast lump, unilateral enlargement, nipple discharge, or rapid progression. NICE NG12 recommends an urgent two-week-wait referral for men aged 50 and over with an unexplained breast lump.

Many men feel embarrassed or uncertain about seeking medical advice for gynaecomastia, but it is important to recognise when professional evaluation is warranted. While the condition is often benign and self-limiting — particularly in adolescents — certain features should prompt a timely GP consultation.

You should see your GP if you notice:

• A firm, rubbery, or tender lump beneath one or both nipples

• Unilateral (one-sided) breast enlargement, which requires careful assessment to exclude malignancy

• Nipple discharge (particularly if bloody), skin changes, or nipple inversion

• Rapid or progressive breast enlargement

• Associated symptoms such as fatigue, unexplained weight loss, testicular pain or swelling, or changes in libido

• Breast changes that are causing significant psychological distress or affecting quality of life

Urgent referral: In line with NICE guideline NG12 (Suspected Cancer: Recognition and Referral), GPs should consider a suspected cancer pathway referral (to be seen within two weeks) for men aged 50 and over with an unexplained breast lump, with or without pain. At any age, features suggesting possible malignancy — including a hard, irregular, or eccentrically positioned lump (not directly beneath the nipple), skin tethering, bloody nipple discharge, or palpable axillary lymph nodes — warrant urgent assessment. A suspicious testicular mass should also prompt an urgent two-week-wait urology referral.

It is worth noting that male breast cancer, whilst rare (accounting for less than 1% of all breast cancers in the UK), can present similarly to gynaecomastia. Any clinical uncertainty should be assessed promptly.

Adolescents experiencing pubertal gynaecomastia can generally be reassured, as the condition resolves spontaneously in the majority of cases within one to two years. However, if it persists beyond the age of 17, or if it is causing significant distress, a GP referral is appropriate. Adults presenting with new-onset gynaecomastia without an obvious cause should always be evaluated to exclude an underlying medical condition or medication effect.

NHS-Recommended Next Steps and Treatment Options

GP assessment includes hormone blood tests, medication review, and targeted investigations. Treatment options range from addressing the underlying cause to off-licence tamoxifen or raloxifene, and surgery in refractory cases.

When a patient presents to their GP with gynaecomastia, the initial assessment will typically involve a thorough history — including medication review, alcohol and recreational drug use, and family history — alongside a physical examination. Blood tests are commonly requested to evaluate hormone levels and exclude underlying conditions.

Typical investigations may include:

• Serum testosterone, luteinising hormone (LH), follicle-stimulating hormone (FSH), and oestradiol

• Prolactin levels (to assess for hyperprolactinaemia)

• Thyroid function tests

• Liver function tests and renal function

• Human chorionic gonadotrophin (hCG) and alpha-fetoprotein (AFP) if a testicular tumour is suspected

• Testicular ultrasound if clinically indicated

In line with NICE guidance and NHS pathways, management depends on the identified cause. Where a causative medication is identified, switching to an alternative agent (where clinically safe and appropriate) may lead to resolution — but this should only be done under medical supervision; do not stop prescribed medicines without advice from your clinician. Treating an underlying condition — such as correcting thyroid dysfunction or managing liver disease — can also result in improvement.

For persistent or distressing gynaecomastia, pharmacological options include tamoxifen (an oestrogen receptor antagonist) or raloxifene. Both are used off-licence in this context, meaning they are not formally approved for this indication in the UK. They are typically initiated by an endocrinologist or specialist following a discussion of the evidence base, potential risks (including venous thromboembolism with tamoxifen), and monitoring requirements. Prescribers and patients can refer to the relevant BNF monographs and electronic Medicines Compendium (emc) Summary of Product Characteristics for full prescribing information. Aromatase inhibitors are generally not recommended for the routine management of gynaecomastia due to limited evidence of benefit and an unfavourable adverse-effect profile.

Surgical intervention — either liposuction or subcutaneous mastectomy — may be considered for longstanding cases where medical treatment has been ineffective. NHS funding for such procedures is subject to local Integrated Care Board (ICB) policies.

If you suspect that a prescribed medicine has contributed to gynaecomastia, this can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Finally, returning to the original question: there is no established link between eating chicken and developing gynaecomastia, and patients can be reassured accordingly. Maintaining a healthy weight, moderating alcohol intake, and having prescribed medicines reviewed regularly remain the most evidence-based strategies for supporting hormonal health in men.

Frequently Asked Questions